DUBAI-ABU DHABI, UAE – Dubai-Abu Dhabi’s biotech and pharmaceutical companies seeking specialized preclinical contract research organization (CRO) services can accelerate their drug discovery timelines with Anilocus. We provide comprehensive preclinical research support specifically designed for the UAE’s dynamic life sciences ecosystem, delivering the regulatory expertise and scientific precision your projects demand.
Supporting the UAE’s Emerging Biotech Powerhouse
Dubai-Abu Dhabi stands as the Middle East’s premier biotechnology hub and gateway to international markets. The UAE region houses over 400 companies employing 4,000 professionals in Dubai Science Park alone, with Abu Dhabi’s new HELM cluster projected to contribute $25.6 billion to GDP and create 30,000 jobs by 2045. The combined emirates generate approximately $293 million in biotechnology and pharmaceutical services revenue, representing the region’s fastest-growing life sciences ecosystem.
The region hosts major pharmaceutical companies including PureHealth, G42 Healthcare, NewBridge Pharmaceuticals, and Pharmax, alongside innovative biotech companies like Virax Biolabs, Hayat Biotech, Biologix, and Dubai-based companies developing breakthrough therapies in genomics, precision medicine, and rare diseases. Dubai-Abu Dhabi’s proximity to world-class research institutions and the region’s strategic position connecting Europe, Asia, and Africa creates an unparalleled environment for collaborative drug discovery and development.
Dubai-Abu Dhabi’s free zone advantages and the UAE’s progressive regulatory framework provide unique benefits for companies targeting Middle Eastern and global markets, with streamlined access to both regional and international regulatory pathways. This established pharmaceutical cluster requires specialized CRO services to support the complex preclinical studies necessary for regulatory approval across multiple jurisdictions.
Why Dubai-Abu Dhabi Biotech Companies Choose Anilocus
- Regional and international regulatory expertise – Deep understanding of UAE and Middle Eastern regulatory requirements alongside FDA and EMA compliance, ensuring smooth transitions from preclinical to clinical phases across multiple jurisdictions
- Specialized in vivo capabilities – Advanced in vivo assessments and custom study designs that complement Dubai-Abu Dhabi’s strength in pharmaceutical innovation and precision medicine development
- Integrated preclinical solutions – Comprehensive study design through regulatory submission support, reducing vendor management complexity and accelerating development timelines for UAE biotech companies
Preclinical CRO Services
Anilocus delivers the full spectrum of preclinical research services that Dubai-Abu Dhabi’s pharmaceutical industry demands. Our capabilities span multiple critical areas of drug development, from initial compound characterization through regulatory submission support.
Pharmacodynamics
Our pharmacodynamics studies determine the biochemical and physiological effects of compounds through receptor binding assays, enzyme inhibition assays, signal transduction assays, functional cell-based assays, and biomarker analysis. These investigations reveal how drug candidates interact with their molecular targets and produce therapeutic effects.
Pharmacokinetics
Pharmacokinetics research characterizes absorption, distribution, metabolism, and excretion properties using plasma concentration-time profiling, bioavailability assays, microsomal stability assays, permeability (Caco-2) assays, and blood-brain barrier penetration assays. This data is essential for understanding drug exposure and designing optimal dosing regimens.
Toxicology
Our toxicology studies assess potential adverse effects through acute toxicity assays, sub-chronic toxicity assays, chronic toxicity assays, maximum tolerated dose (MTD) assays, and no observed adverse effect level (NOAEL) determination. These comprehensive evaluations establish safe dose ranges and identify target organs of toxicity.
Safety Pharmacology
Safety pharmacology investigations examine effects on vital physiological systems using hERG channel inhibition assays, ECG telemetry assays, respiratory rate monitoring, locomotor activity assays, and core body temperature assays. This ensures drug candidates don’t adversely affect cardiovascular, respiratory, or central nervous system function.
Bioanalytics Testing for Dubai-Abu Dhabi Biotech
Genotoxicity
Our genotoxicity studies evaluate genetic damage potential through Ames tests, in vitro micronucleus assays, chromosomal aberration assays, comet assays, and mouse lymphoma assays. These investigations are crucial for identifying compounds that might cause cancer or heritable defects.
Reprotox
Reproductive and developmental toxicology assessments examine drug impact on fertility and development using fertility and early embryonic development assays, embryo-fetal development assays, prenatal and postnatal development assays, teratogenicity assays, and sperm morphology assays. These studies ensure reproductive safety across generations.
Immunotoxicity
Our immunotoxicology services detect immune system effects through T-cell proliferation assays, natural killer cell activity assays, delayed-type hypersensitivity assays, hemagglutination titer assays, and cytokine release assays. This identifies potential immunosuppression, hypersensitivity, or autoimmunity risks.
Carcinogenicity
For compounds intended for chronic use, our carcinogenicity studies assess long-term tumor formation potential using rodent bioassays (2-year studies), initiation-promotion assays, transgenic mouse models (e.g., rasH2), cell transformation assays, and DNA adduct formation assays.
Ready to Accelerate Your Dubai-Abu Dhabi Biotech Research?
Ready to advance your preclinical research with a CRO partner that understands Dubai-Abu Dhabi’s pharmaceutical ecosystem and regulatory landscape? From university spinouts to established pharmaceutical companies in the HELM cluster and Dubai Science Park, Anilocus delivers the scientific excellence that forward-thinking UAE biotech companies demand.
Get Started Today!
Transform your research vision into actionable data with Anilocus, where scientific precision meets custom fabrication capability for real research impact. Contact us today and speak to a scientist about your Dubai-Abu Dhabi biotech project!
Keep Reading
- G42 Healthcare and PureHealth Launch Revolutionary AI-Driven Drug Discovery Platform – Discover how UAE’s leading biotech companies are leveraging artificial intelligence for collaborative pharmaceutical research and development.
- Dubai Science Park Unveils $2.8B Expansion for Next-Generation Biotech Manufacturing – Explore how Dubai’s premier life sciences hub addresses growing demand for advanced biotechnology research and production facilities.
- UAE Introduces Fast-Track Biotech Approval System for International Companies – Understand how recent regulatory updates specifically benefit UAE’s pharmaceutical companies seeking accelerated drug development and market entry pathways.
